ESMO Congress 2022
ESMO 2022 Prostate Cancer
- ESMO 2022: Lu-PSMA for Prostate Cancer Treatment
- ESMO 2022: Invited Discussant: Results of RADICALS-HD
- ESMO 2022: Observations on the Biology of PSMA Implications for Targeting
- ESMO 2022: PSMA Targeted T Cell Engagers
- ESMO 2022: Duration of Androgen Deprivation Therapy with Post-Operative Radiotherapy for Prostate Cancer First Results of the RADICALS-HD Trial ISRCTN40814031
ESMO 2022 Bladder Cancer
- ESMO 2022: Latest Imaging Advances in PET and Beyond Translated to Bladder and Kidney Cancers
- ESMO 2022: Invited Discussant: The Phase III VESPER Trial & the Phase III CheckMate 274 Trial
- ESMO 2022: Pure or Mixed Basal/squamous Tumours Present Decreased Outcomes After Neoadjuvant Chemotherapy in the GETUG-AFU V05 VESPER Trial
- ESMO 2022: Tumor and Immune Features Associated with Disease-Free Survival with Adjuvant Nivolumab in the Phase 3 CheckMate 274 Trial
- ESMO 2022: Study EV-103 Cohort K: Antitumor Activity of Enfortumab Vedotin Monotherapy or in Combination with Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
ESMO 2022 Testicular and Penile Cancer
- ESMO 2022: Invited Discussant: The Challenges and Opportunities Present in the Treatment of Rare Genitourinary Cancers Discussion
- ESMO 2022: Risk and Mortality of Testicular Cancer in Patients with Psychiatric or Neurodevelopmental Disorders
- ESMO 2022: Outcomes of Relapsed Clinical Stage I Versus De Novo Metastatic Testicular Cancer Patients: An Analysis of the IGCCCG Update Database
- ESMO 2022: Neoadjuvant Platinum-Based Chemotherapy (NAPC) for Metastatic Penile Squamous Cell Carcinoma (PSCC): An International, Multicenter, Real-World Study
ESMO 2022 Press Releases
- Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
- New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
- Great Oaks Grow from Small Acorns: Oncology Is Committed to Doing Its Part for Sustainability
- Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
- Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
ESMO 2022 Kidney Cancer
- ESMO 2022: Invited Discussant: Results of COSMIC-313
- ESMO 2022: Multidisciplinary Updates in Biomarkers in Urinary Cancers: The Microbiome
- ESMO 2022: Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma of IMDC Intermediate or Poor Risk (COSMIC-313)
- ESMO 2022: Invited Discussant: BIONIKK trial, Changes in Gut Microbiota, & LITESPARK-004 trial
- ESMO 2022: Invited Discussant: The Results of the PIVOT-09 Trial & the Role of Enfortumab Vedotin